Abstract
Background The PARADIGM-HF trial showed that sacubitril-valsartan - an angiotensin receptor-neprilysin inhibitor (ARNI) - is more effective than enala......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
